Teniposide in adult solid tumors: a historical perspective

Area of Science:

• Oncology
• Pharmacology

Background:

• Teniposide and etoposide are semi-synthetic epipodophyllotoxin derivatives.
• Etoposide gained prominence due to formulation advantages, overshadowing teniposide research.
• Early teniposide trials showed promise despite suboptimal dosing and scheduling.

Purpose of the Study:

• To reevaluate teniposide's potential in cancer treatment.
• To explore teniposide's efficacy against various malignancies, including lymphomas, leukemias, and SCLC.
• To investigate optimal dosing, scheduling, and formulations for teniposide therapy.

Main Methods:

• Review of early phase I and II clinical trial data for teniposide.
• Comparison of teniposide's antitumor activity with that of etoposide.
• Identification of potential new indications and areas for further clinical investigation.

Main Results:

• Teniposide demonstrates substantial antitumor activity comparable to etoposide.
• Early studies indicated encouraging results against small cell lung cancer (SCLC), lymphomas, and leukemias.
• Teniposide showed potential in treating childhood solid tumors and ovarian cancer.

Conclusions:

• Teniposide warrants reevaluation for treating lymphomas, Hodgkin's disease, leukemias, and SCLC.
• Further investigation into its use for brain tumors, neuroblastomas, ovarian, gastric, and breast cancers is suggested.
• Optimized formulations and administration routes could enhance teniposide's role in cancer chemotherapy.